Bayer and Novartis appeal ruling that Avastin for wet AMD is lawful

@article{Cohen2018BayerAN,
  title={Bayer and Novartis appeal ruling that Avastin for wet AMD is lawful},
  author={Deborah Cohen},
  journal={British Medical Journal},
  year={2018},
  volume={363}
}
  • D. Cohen
  • Published 30 October 2018
  • Political Science, Medicine
  • British Medical Journal
The drug companies Bayer and Novartis plan to appeal against a High Court ruling that gave doctors the right to offer patients off-label bevacizumab to treat wet age related macular degeneration (AMD). Both claim that the judgment is wrong because it undermines the role of drug regulatory agencies in the UK and Europe and puts public health at risk. Bayer and Novartis brought legal proceedings against 12 clinical commissioning groups (CCGs) in the north of England for offering bevacizumab… Expand
2 Citations
Novel method of treating macular degeneration: a patent evaluation (WO2018/107005)
TLDR
The botulinum-toxin is administrated as extra-ocular infusions avoiding the risk of direct intraocular injection and the complications associated with the patients and the possibility to administer BT with accessory proteins makes the novel system interesting for developing combined approaches for AMD treatment. Expand
Companies plan to appeal ruling on bevacizumab for wet AMD
  • PharmacoEconomics & Outcomes News
  • 2018

References

CCGs win right to offer patients Avastin for wet AMD
  • D. Cohen
  • Medicine
  • British Medical Journal
  • 2018
A group of 12 clinical commissioning groups in the north of England have won a legal battle to offer patients a choice to use off-label bevacizumab to treat wet age related macular degeneration,Expand